RxDoctor Payments Data

Manuel Cerqueira, MD

Nuclear Medicine · Cleveland, OHNPI 1356304232

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $136,693 of the $160,293 with a category attached, or 85.3%. Astellas Pharma US Inc accounts for 70.4% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $91,929 and has fallen 89.7% since, to $9,444 in 2022.

$160,293in general payments, 2019–2025

Across 140 payments — averaging $1144.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$113K
  • GE HealthCare$37K
  • Pfizer$9K
  • Siemens Medical Solutions USA, Inc.$1K
  • Agfa Healthcare Corporation$223
  • Advanced Accelerator Applications$78
  • plus $65 from 2 others

What the payments were for

  • Consulting fees$11,1497%
  • Speaking & faculty fees$136,69385%
  • Travel & lodging$9,5976%
  • Food & beverage$2,8532%

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Astellas Pharma US Inc108$112,804
GE HealthCare6$37,040
Pfizer4$8,901
Siemens Medical Solutions USA, Inc.15$1,182
Agfa Healthcare Corporation1$223
Advanced Accelerator Applications3$78
Bayer2$40
Blue Earth Diagnostics1$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few nuclear medicine providers in Ohioto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$53,799
Medicare patients
699
Services billed
708

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other nuclear medicine in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →